Investment Considerations
- The company combines proprietary imaging hardware, FDA-cleared AI applications, cloud software, radiology services and healthcare IT within an end-to-end platform spanning scan, analysis and interpretation.
- Nanox is expanding its commercial reach through its U.S. commercial activities and collaboration with healthcare organizations.
- First-quarter 2026 revenue increased to $4.3 million from $2.8 million in the prior-year period, with contributions from teleradiology, imaging systems, OEM services, AI, software and Health IT.
- Nanox has secured FDA clearance for Nanox.ARC, Nanox.ARC X and three Nanox.AI medical imaging solutions, while its commercial and clinical activities involve organizations including RadNet, Cedars-Sinai, Corewell Health and Brigham and Women’s Hospital.
Nanox (NASDAQ: NNOX) is focused on driving the world’s transition to preventive health care by delivering an integrated, end-to-end medical imaging and healthcare services platform.
Nanox combines affordable imaging hardware, advanced AI-based solutions, cloud-based software, access to remote radiology, health IT solutions, and a marketplace to enable earlier detection, improved clinical efficiency, and broader access to care.
Nanox’s vision is to expand the reach of medical imaging both within and beyond traditional hospital settings by providing a seamless solution from scan to interpretation and beyond. By leveraging proprietary digital X-ray technology, AI-driven analytics, and a clinically driven approach, Nanox aims to enhance the efficiency of routine imaging workflows, support early detection of disease, and improve patient outcomes.
The Nanox ecosystem includes Nanox.ARC, a cost-effective, 3D multi-source digital tomosynthesis imaging system designed for ease of use and scalability; Nanox.AI, a suite of AI-based algorithms that augment the interpretation of routine CT imaging to identify early signs often associated with chronic disease; Nanox.CLOUD, a cloud-based platform for secure data management, storage, and advanced imaging analytics; Nanox.MARKETPLACE and USARAD Holdings, which provide access to remote radiology and cardiology experts and comprehensive teleradiology services; and Nanox Health IT, which combines deep healthcare IT expertise with leading technology partners to deliver RIS, PACS, AI, dictation, and secure infrastructure solutions that streamline workflows and support safer, more efficient care delivery.
Technology and Services
Nanox.ARC
Nanox.ARC is an FDA-cleared and CE-marked stationary digital multi-source tomosynthesis system that produces three-dimensional radiographic images while reducing the superimposition of anatomical structures. The company offers the system through a capital-purchase model or a pay-per-scan medical screening-as-a-service (MSaaS) model that does not require an upfront capital expenditure.
Nanox.ARC X is the company’s next-generation, FDA-cleared system, combining a compact 15-by-10-foot space requirement and standard 110-volt power connection with the ability to generate up to 200 coronal images per scan. According to Nanox, the system delivers approximately 80% less radiation than a CT scan, can be billed under CPT code 76100 and is designed to receive future capabilities remotely following applicable regulatory clearance.
A Nanox.ARC system was also in commercial use and integrated into routine clinical workflow at a RadNet facility.
Nanox.AI
Nanox.AI is the deep-learning medical imaging analytics subsidiary of Nanox. Nanox.AI solutions are developed to target highly prevalent chronic and acute diseases affecting large populations around the world. Leveraging AI, Nanox.AI helps clinicians extract valuable and actionable clinical insights from medical imaging that otherwise may go unnoticed, potentially initiating further medical assessment to establish individual preventative care pathways for patients. Nanox states that its AI technology draws on 30 million patient records, 10 years of patient history and 500 million images across multiple imaging modalities. In one reported deployment, Corewell Health used the cardiac solution to identify nearly 4,000 new patients with coronary artery calcification in 2023, compared with 268 patients whose calcification had been reported during the preceding two years.
In July 2026, Nanox announced that data from studies involving Brigham and Women’s Hospital, Massachusetts General Hospital, the University of Texas Southwestern Medical Center and other institutions would be presented at the Society of Cardiovascular Computed Tomography’s annual scientific meeting. The studies evaluated HealthCCSng’s agreement with expert assessment and whether AI-detected coronary calcium could help clinicians identify opportunities for preventive lipid-lowering therapy.
Nanox.CLOUD
Nanox.CLOUD supports image processing, radiology services and Nanox.ARC fleet management through capabilities including cloud-based image reconstruction, centralized protocol management, continuous updates and remote support. The platform can be hosted locally or in the cloud and is designed for HIPAA and GDPR compliance.
Other Technology and Services
The remainder of the Nanox ecosystem includes USARAD’s teleradiology services, Nanox.MARKETPLACE’s web-based connection of imaging facilities with diagnostic expertise, and Nanox Health IT’s healthcare IT solutions, including RIS, PACS, AI, dictation and secure infrastructure offerings.
Nanox also offers its proprietary cold-cathode X-ray source and tube technology, a core component of the company’s imaging platform, to original equipment manufacturers through hardware, licensing and royalty arrangements for potential medical, industrial and security applications.
Leadership Team
Erez Meltzer, Chief Executive Officer and Acting Chairman of the Board, leads Nanox after previously serving for six years as chairman of Hadassah Medical Center in Israel. His career also includes leadership roles at Gadot Chemicals & Shipping Group, Africa Israel, Netafim and Creo Scitex.
Guy Nathanzon, Chief Financial Officer, has held senior CFO and COO positions at U.S. publicly traded companies and medical technology businesses, with experience supporting commercialization, organizational growth and global operations. He previously served as CFO of AI-based medical diagnostics company Scopio Labs and most recently served as CFO of New York Stock Exchange-listed Valens Semiconductor.